Mechanistic target of rapamycin complex (mTOR complex (commonly subdivided as mTORC1 and mTORC2))

The **mechanistic target of rapamycin complex** refers collectively to two distinct multi-protein assemblies—**mTOR Complex 1 (mTORC1)** and **mTOR Complex 2 (mTORC2)**—each containing the serine/threonine-protein kinase known as mechanistic target of rapamycin (**mTOR**). These complexes act as central regulators integrating signals from nutrients, energy status, growth factors, hormones, and stress conditions. **mTORC1**, composed mainly of mTOR itself along with Raptor and other subunits such as mLST8, PRAS40, and DEPTOR, functions primarily as a nutrient/energy/redox sensor. It controls protein synthesis by phosphorylating key effectors like S6K and 4EBP proteins. Its activation is tightly regulated by amino acids (notably leucine), insulin/growth factors via PI3K/Akt pathway signaling, mechanical stimuli, oxidative stress—and it is acutely sensitive to inhibition by the drug rapamycin. **mTORC2**, which includes RICTOR instead of Raptor among its core components along with shared subunits like MLST8/mLST8B/SIN proteins etc., regulates cytoskeletal organization through actin dynamics. It also modulates metabolism and survival pathways by phosphorylating AGC kinases such as Akt at Ser473—a modification required for full Akt activation—as well as SGK family kinases. Dysregulation or hyperactivation/mutation in either/both complexes has been implicated in a wide range of diseases including cancer progression/resistance mechanisms; neurodegeneration; cardiovascular pathologies; metabolic syndromes such as obesity/type II diabetes; among others. Pharmacological targeting—most notably using allosteric inhibitors like rapalogs—has shown clinical benefit but also presents challenges related to immunosuppression/metabolic side effects.

Other names

Mammalian target of rapamycin complexmTORC1 (mTOR Complex 1)mTORC2 (mTOR Complex 2)FK506-binding protein 12-rapamycin-associated protein complexes

Inhibition of serine/threonine kinase activity, primarily by binding to the FKBP12–rapamycin binding domain, leading to suppression of downstream signaling pathways involved in cell growth and proliferation. Allosteric inhibition via drug-induced conformational changes that disrupt substrate recruitment or phosphorylation.